Santhera Pharmaceuticals has announced a special agreement with Ikris Pharma Network to provide AGAMREE to patients in India. AGAMREE is designed to treat Duchenne muscular dystrophy in children who are four years old or older. The partnership will last for five years, and during that time, Santhera will receive a portion of the revenue from sales. The product is expected to be available starting in the fourth quarter of 2025, initially for individual patients who have been specifically identified.

Health Technology Insights: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies

This agreement follows Santhera’s recent partnerships in Turkey and the Gulf Cooperation Council countries, as the company works to make AGAMREE available to more people around the world. Expanding access to this treatment remains a priority as Santhera continues its global rollout.

Santhera’s CEO, Dario Eklund, expressed enthusiasm about collaborating with Ikris Pharma Network. He praised their deep understanding of Duchenne muscular dystrophy and their commitment to helping patients with rare diseases. He added that this partnership aligns well with Santhera’s goal of broadening access to this vital therapy.

Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 25 August 2025

Praveen Sikri, founder and CEO of Ikris Pharma Network, stated that the partnership fits with their mission to address the challenges faced by rare disease patients. He emphasized their readiness to leverage their extensive distribution network to ensure that patients in India can obtain this innovative treatment.

Both leaders are optimistic about the impact this collaboration will have on the lives of those affected by Duchenne muscular dystrophy. They believe the partnership will improve access to care and bring hope to many families across India.

Health Technology Insights: Vivo Care, Tenovi Partner on Remote Monitoring Expansion

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com